NEMLUVIO relieves itch fast, with skin healing that lasts1
Fast Itch Relief1
See how NEMLUVIO significantly improved itch in both pivotal and long-term studies1
Lasting Skin Healing1
Discover how NEMLUVIO healed most PN nodules for patients with PN1
Sleep Improvement1
Patients saw meaningful improvements in their sleep while taking NEMLUVIO1
Favorable Safety Profile1
NEMLUVIO offers a favorable safety profile and requires no preliminary lab evaluations or ongoing lab monitoring1
A Trial Designed to Capture the Complexity of PN2,3
Explore the design of OLYMPIA, the largest controlled clinical trial program in PN4
Sign up now for more information about NEMLUVIO and PN
PN=prurigo nodularis.
References: 1. Galderma Laboratories, L.P.; data on file. 2. NEMLUVIO (nemolizumab-ilto) injection 30 mg Prescribing Information. Dallas, TX: Galderma Laboratories, L.P.; August 2024. 3. Galderma Laboratories, L.P.; data on file. Clinical Study Report RD.06.SRE.203065; September 2023. 4. Galderma phase Ill data published in The New England Journal of Medicine: full Olympia 2 trial results demonstrate nemolizumab's rapid onset of action in patients with prurigo nodularis. Galderma Laboratories, L.P. Press release. Published October 26, 2023. Accessed April 18, 2024.